1 M o n t r e a l P r o t o c o l M O P m e e t i n g, N o v e m b e r , B a n g k ok TEAP/MTOC Addendum Report Review of Revised Essential Use Nomination from Bangladesh for 2011

MTOC is pleased to report that: The essential use nomination from India for 2011 for tonnes CFC for MDIs has been withdrawn. The essential use nomination from Iran for 2011 for 105 tonnes CFCs for MDIs has been withdrawn. Both countries have successfully phased out CFC MDIs, ahead of schedule in the case of India. MTOC wishes to commend to the Parties the outstanding transition achievements of India and Iran, their industries and technology transfer partners, and their dedication to asthma patients and the ozone layer. Update on progress in CFC MDI phase-out M o n t r e a l P r o t o c o l M O P - 22 m e e t i n g, N o v e m b e r , B a n g k ok

At the 30th OEWG, Bangladesh held bilateral discussions with MTOC about its essential use nomination for CFC MDIs for Bangladesh requested TEAP and its MTOC to reassess Bangladeshs nomination. MTOC requested additional information from Bangladesh in order to undertake the review. Bangladesh submitted additional information with a revised nomination in September/October Bangladesh reduced its EUN from to 85 tonnes of CFCs. Review of Revised Essential Use Nomination from Bangladesh for 2011 M o n t r e a l P r o t o c o l M O P - 22 m e e t i n g, N o v e m b e r , B a n g k ok

Total capacity of salbutamol and beclomethasone HFC MDI manufacture in Bangladesh will be 25 million units/yr by the end of Adequate capacity for Bangladesh MDI consumption (~5 million units/yr) is available for these active ingredients. Bangladesh argues that physicians and patients need more time to get accustomed to HFC inhalers, and wishes to complete its awareness activities before deregistering CFC inhalers in about MTOC sees little benefit in delaying transition of these single moieties for a further 12 months. MTOC Findings M o n t r e a l P r o t o c o l M O P - 22 m e e t i n g, N o v e m b e r , B a n g k ok

Taking into account the revised quantities nominated, MTOC recommends 37.0 tonnes of CFCs for MDIs for use in Bangladesh only for ciclesonide, fluticasone/ salmeterol, ipratropium, ipratropium/salbutamol, salmeterol and tiotropium. MTOC is unable to recommend CFCs for MDIs for active ingredients beclomethasone, levosalbutamol and salbutamol due to the availability of alternatives. MTOC Recommendation M o n t r e a l P r o t o c o l M O P - 22 m e e t i n g, N o v e m b e r , B a n g k ok